Bivalirudin fails to prevent atrial thrombus development in heparin-induced thrombocytopaenia and thrombosis syndrome.
Alexandru TopliceanuThomas J BreenHiren PatelNeil YagerErica MaceiraMikhail TorosoffPublished in: BMJ case reports (2018)
An 81-year-old woman presented with acute decompensated heart failure due to new-onset atrial fibrillation and a flail myxomatous mitral valve which necessitated surgical mitral valve repair. No atrial thrombi were noted on transoesophageal echocardiograms performed prior to surgery and intraoperatively. Immediately postoperatively, while treated with unfractionated heparin, the patient developed thrombocytopaenia with positive platelet factor 4 antibodies and an abnormal serotonin functional platelet assay, consistent with heparin-induced thrombocytopaenia. The anticoagulation therapy was changed to the direct thrombin inhibitor bivalirudin with an improvement in the platelet count. Despite bivalirudin therapy, a left atrial layering thrombus was revealed on transoesophageal echocardiogram performed in preparation for cardioversion of the symptomatic atrial fibrillation. Anticoagulation was changed to warfarin, and the patient was discharged without thromboembolic complications neither during her hospital stay nor the 3-year outpatient follow-up.
Keyphrases
- atrial fibrillation
- left atrial
- heart failure
- left atrial appendage
- percutaneous coronary intervention
- catheter ablation
- oral anticoagulants
- case report
- mitral valve
- venous thromboembolism
- direct oral anticoagulants
- coronary artery bypass
- drug induced
- high glucose
- liver failure
- diabetic rats
- minimally invasive
- growth factor
- left ventricular
- coronary artery disease
- healthcare
- pulmonary embolism
- emergency department
- oxidative stress
- risk factors
- cardiac resynchronization therapy
- endothelial cells
- cell therapy
- extracorporeal membrane oxygenation